Infinium Pharmachem Ltd
Incorporated in 2003, Infinium Pharmachem Ltd manufactures and sells Iodian based Pharmaceutical Intermediates[1]
- Market Cap ₹ 346 Cr.
- Current Price ₹ 222
- High / Low ₹ 337 / 214
- Stock P/E 37.1
- Book Value ₹ 73.7
- Dividend Yield 0.00 %
- ROCE 14.6 %
- ROE 12.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
- Company has delivered good profit growth of 61.0% CAGR over last 5 years
- Company has a good return on equity (ROE) track record: 3 Years ROE 21.6%
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -5.33%
- Debtor days have increased from 61.2 to 79.1 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|
| 39 | 71 | 99 | 114 | 136 | 156 | 157 | |
| 36 | 66 | 89 | 98 | 117 | 136 | 138 | |
| Operating Profit | 2 | 5 | 10 | 16 | 19 | 19 | 18 |
| OPM % | 6% | 7% | 10% | 14% | 14% | 12% | 12% |
| 1 | 1 | 1 | 1 | 2 | -1 | 2 | |
| Interest | 1 | 1 | 2 | 3 | 2 | 4 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 3 | 3 | 3 |
| Profit before tax | 1 | 4 | 9 | 13 | 15 | 12 | 13 |
| Tax % | 30% | 28% | 23% | 24% | 24% | 32% | |
| 1 | 3 | 7 | 10 | 12 | 8 | 10 | |
| EPS in Rs | 4.65 | 13.60 | 30.55 | 9.30 | 8.12 | 5.23 | 5.99 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 32% |
| 3 Years: | 16% |
| TTM: | 0% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 61% |
| 3 Years: | 18% |
| TTM: | -2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 25% |
| 3 Years: | 22% |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 5 | 14 | 16 | 16 |
| Reserves | 3 | 6 | 12 | 17 | 45 | 94 | 99 |
| 9 | 11 | 23 | 29 | 11 | 52 | 0 | |
| 9 | 17 | 23 | 19 | 15 | 37 | 75 | |
| Total Liabilities | 22 | 34 | 59 | 71 | 85 | 198 | 190 |
| 4 | 5 | 4 | 19 | 20 | 24 | 24 | |
| CWIP | 0 | 4 | 8 | 0 | 0 | 1 | 5 |
| Investments | 0 | 0 | 0 | 0 | 0 | 29 | 29 |
| 18 | 26 | 46 | 52 | 66 | 144 | 132 | |
| Total Assets | 22 | 34 | 59 | 71 | 85 | 198 | 190 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 3 | 7 | 12 | 9 | 5 | -29 | |
| -1 | -5 | -7 | -5 | -4 | -27 | |
| -1 | -1 | -2 | -3 | 5 | 79 | |
| Net Cash Flow | 1 | 1 | 3 | 1 | 6 | 23 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 75 | 59 | 57 | 49 | 55 | 79 |
| Inventory Days | 84 | 62 | 78 | 89 | 87 | 137 |
| Days Payable | 82 | 79 | 56 | 31 | 16 | 38 |
| Cash Conversion Cycle | 76 | 43 | 78 | 108 | 126 | 178 |
| Working Capital Days | 46 | 12 | 25 | 27 | 96 | 97 |
| ROCE % | 32% | 38% | 36% | 28% | 15% |
Documents
Announcements
-
Investor Presentation
24 November 2025 - Presentation of unaudited H1FY26 results; contrast-media project concluding Dec 2025; FY26 revenue target Rs200 Crore.
-
Analysts/Institutional Investor Meet/Con. Call Updates
19 November 2025 - Infinium Pharmachem meeting at GIA Small Cap Day 2025, in-person, 24 Nov 2025, 9:00–17:00 IST, BKC Mumbai.
-
Copy of Newspaper Publication
18 November 2025 - Unaudited H1 FY26 standalone and consolidated results approved Nov 13, published Nov 18, 2025.
-
Outcome of Board Meeting
13 November 2025 - Half-year ended 30 Sep 2025: standalone total income Rs7,298.74 Lacs, PBT Rs628.29 Lacs; consolidated total income Rs8,405.08 Lacs, PBT Rs833.03 Lacs.
-
Outcome of Board Meeting
13 November 2025 - Unaudited standalone and consolidated H1 results (30 Sep 2025) approved; PBT Rs628.29L standalone, Rs833.03L consolidated.
Annual reports
Concalls
-
Nov 2025TranscriptAI SummaryPPT
-
Jun 2024Transcript PPT REC
-
Mar 2024Transcript PPT
Business Overview:[1]
IPL is a GMP compliant, FDA Approved and ISO 9001-2015 certified coimpany which does development, manufacture, and export of Iodine Derivatives & API. Currently, it has 250+ intermediates and 15+ APIs. It supplies a range of Iodine derivatives on Order to Made basis